Helen M. Thackray's Net Worth

$2.27 Million

Estimate Recalculated Jun 25, 2024 03:41PM EST

Who is Helen M. Thackray?

Helen M. Thackray has an estimated net worth of $2.27 Million. This is based on reported shares across multiple companies, which include ImmunoGen, Inc., BIOCRYST PHARMACEUTICALS INC, and GLYCOMIMETICS INC.

SEC CIK

Helen M. Thackray's CIK is 0001589725

Past Insider Trading and Trends

2021 was Helen M. Thackray's most active year for acquiring shares with 8 total transactions. Helen M. Thackray's most active month to acquire stocks was the month of December. 2016 was Helen M. Thackray's most active year for disposing of shares, totalling 6 transactions. Helen M. Thackray's most active month to dispose stocks was the month of June. 2021 saw Helen M. Thackray paying a total of $262,680.00 for 926,500 shares, this is the most they've acquired in one year. In 2022 Helen M. Thackray cashed out on 10,725 shares for a total of $157,151.25, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

ImmunoGen, Inc. (IMGN) Snapshot price: $29.5

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-3.07K
—
—
0
Feb 12
Form 4
+8.93%
252
$29.65
$7,471.80
3.07K
Dec 29
Form 4
+20.09%
472
$15.87
$7,490.64
2.82K
Sep 29
Form 4
+20.33%
397
$18.87
$7,491.39
2.35K
Jun 30
Form 4
—
0
—
—
0
Jun 14
Form 4
∞
1.95K
$3.84
$7,499.52
1.95K
Mar 31
Form 4
—
0
—
—
0
Jun 15
Form 4
—
0
—
—
0
Sep 22
Form 3
—
0
—
—
0
No matching records found

BIOCRYST PHARMACEUTICALS INC (BCRX) Snapshot price: $5.305

Chief R&D Officer

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+12.39%
30K
$5.86
$175,800.00
272.14K
May 14
Form 4
-3.01%
-7.53K
$5.08
-$38,227.00
242.14K
Mar 31
Form 4
-2.19%
-5.58K
$6.05
-$33,759.00
249.66K
Dec 19
Form 4
+23.14%
47.97K
$6.43
-$19,489.33
255.24K
Dec 14
Form 4
-3.27%
-7.00K
$8.29
-$58,030.00
207.28K
Apr 3
Form 4
+60.78%
81K
—
—
214.28K
Dec 19
Form 4
-2.29%
-3.13K
$10.89
-$34,031.25
133.28K
Scheduled
Dec 15
Form 4
-5.28%
-7.60K
$16.20
-$123,120.00
136.4K
Scheduled
Apr 1
Form 4
+44.00%
44K
—
—
144K
Dec 14
Form 4
∞
100K
—
—
100K
Mar 31
Form 4
—
0
—
—
0
May 12
Form 4
—
0
—
—
0
Sep 20
Form 3
—
0
—
—
0
No matching records found

GLYCOMIMETICS INC (GLYC) Snapshot price: $3.17

SVP Clinical Development, CMO

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+23.21%
34.5K
—
—
183.12K
Jan 20
Form 4
—
0
—
—
0
Jan 22
Form 4
—
0
—
—
0
Jan 17
Form 4
—
0
—
—
0
Jan 10
Form 4
-1.33%
-2.00K
$15.01
-$30,020.00
148.62K
Scheduled
Dec 8
Form 4
-1.31%
-2.00K
$13.00
-$26,000.00
150.62K
Scheduled
Sep 18
Form 4
-1.29%
-2.00K
$15.57
-$31,140.00
152.62K
Scheduled
May 25
Form 4
-1.28%
-2.00K
$12.14
-$24,280.00
154.62K
Scheduled
May 19
Form 4
—
0
—
—
0
Jan 4
Form 4
-2.49%
-4.00K
$7.00
-$28,001.00
156.62K
Scheduled
Oct 3
Form 4
-1.23%
-2.00K
$8.00
-$16,000.00
160.62K
Scheduled
Jul 20
Form 4
-11.92%
-22.00K
$7.00
-$153,953.84
162.62K
Scheduled
Jul 1 - Jul 6
Form 4
—
0
—
—
0
Jan 7
Form 4
—
0
—
—
0
Jan 8
Form 4
—
0
—
—
0
Jan 9
Form 3
—
0
—
—
0
No matching records found